• News
  • SAN DIEGO
  • Technology

Genelux appoints John Prunty as chief financial officer

San Diego-based Genelux Corp.’s Board of Directors has appointed John D. Prunty chief financial officer, effective Feb.10.

Genelux is a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics.

Prior to joining Genelux Corp., Prunty served as senior vice president, chief financial officer and corporate secretary of Optimer Pharmaceuticals, a San Diego-based biotech focused on anti-infective development, from 2006 until mid 2012.

Before his tenure at Optimer, Prunty held several key positions with Maxim Pharmaceuticals Inc., a biopharmaceutical company, from 2000 to 2006, including chief financial officer, vice president of finance, and corporate secretary.

Prunty served as senior director of finance and corporate controller at Gen-Probe Inc. from 1997 to 2000. He also held senior management positions at I-Bus, which was a division of Maxwell Technologies Inc., an electronic device company.

Prunty began his career as an auditor at Ernst & Young LLP where he spent seven years in public accounting. He is a certified public accountant and received a B.B.A. from the University of San Diego and an master’s degree in management from San Diego State University.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.